Hormonal
Gut microbiota composition influences metabolic health through the production of short-chain fatty acids (SCFAs) like butyrate, which have anti-inflammatory properties and improve insulin sensitivity, and through the modulation of gut hormones like GLP-1 and PYY.
Eating fermentable fibers (prebiotics) feeds beneficial gut bacteria that produce short-chain fatty acids like butyrate. These compounds reduce inflammation and improve insulin sensitivity. Additionally, certain fibers stimulate the release of satiety hormones (GLP-1, PYY), helping regulate appetite and blood sugar.
increasing plasma levels of butyrate improve insulin sensitivity and increase energy expenditure in animal models of diet-induced obesity... modulation of gut peptides involved in the control of glucose homeostasis could be one mechanism by which the modulation of gut microbiota via specific dietary fibres is associated with an improvement of metabolic disorders.
Why this rating
Supported by animal studies and some human observational data, but causal links in humans are still under investigation (e.g., FATLOSE trial mentioned as ongoing).
Source
The environment within: how gut microbiota may influence metabolism and body composition
A. Vrieze et al. · Diabetologia · 2010
DOI 10.1007/s00125-010-1662-7
More from this paper
- Gastric bypass surgery (GBP) improves glucose metabolism and reduces obesity risk partly by altering gut microbiota composition and increasing the secretion of gut hormones (GLP-1, PYY), often before significant weight loss occurs.Good
- Gut microbiota composition influences body weight and metabolic health by increasing energy harvest from diet and modulating host fat storage pathways, with obese individuals harboring microbiota that extract more energy from the same diet than lean individuals.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →